431 related articles for article (PubMed ID: 15366789)
1. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
2. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.
Bulur S; Ozhan H; Erden I; Alemdar R; Aydin M; Caglar O; Basar C; Ordu S
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):29-33. PubMed ID: 20975532
[TBL] [Abstract][Full Text] [Related]
4. White coat hypertension and haemostatic/fibrinolytic balance disorders.
Makris T; Stavroulakis G; Papadopoulos D; Paizis I; Krespi P; Tsoukala C; Hatzizacharias A; Votteas V
Eur Cytokine Netw; 2006 Jun; 17(2):137-41. PubMed ID: 16840033
[TBL] [Abstract][Full Text] [Related]
5. AT1 blockers and uric acid metabolism: are there relevant differences?
Puig JG; Torres R; Ruilope LM
J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
[TBL] [Abstract][Full Text] [Related]
6. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[TBL] [Abstract][Full Text] [Related]
7. Losartan increases bradykinin levels in hypertensive humans.
Campbell DJ; Krum H; Esler MD
Circulation; 2005 Jan; 111(3):315-20. PubMed ID: 15655136
[TBL] [Abstract][Full Text] [Related]
8. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
9. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
Ametov AS; Demidova TIu; Kosykh SA
Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
13. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[TBL] [Abstract][Full Text] [Related]
14. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
15. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
[TBL] [Abstract][Full Text] [Related]
16. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
17. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
[TBL] [Abstract][Full Text] [Related]
18. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A; Hanon O; Negre-Pages L; Sevenier F;
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
